Glucotrack's Losses Widen Amid Clinical Progress, Liquidity Concerns

Ticker: GCTK · Form: 10-Q · Filed: Nov 13, 2025 · CIK: 1506983

Glucotrack, INC. 10-Q Filing Summary
FieldDetail
CompanyGlucotrack, INC. (GCTK)
Form Type10-Q
Filed DateNov 13, 2025
Risk Levelhigh
Pages15
Reading Time18 min
Key Dollar Amounts$1
Sentimentbearish

Sentiment: bearish

Topics: Medical Devices, Diabetes Management, Clinical Trials, Going Concern, Biotechnology, Cash Burn, Reverse Stock Split

TL;DR

**GCTK is burning cash fast, and while clinical data looks good, the going concern warning means this is a high-risk bet on future financing.**

AI Summary

Glucotrack, Inc. (GCTK) reported a net loss of $15.76 million for the nine months ended September 30, 2025, an increase from $12.503 million in the same period of 2024. Operating expenses rose to $12.603 million from $10.693 million year-over-year, driven by increased research and development expenses of $8.186 million, up from $7.800 million. The company's cash and cash equivalents increased to $7.869 million as of September 30, 2025, from $5.617 million at December 31, 2024, primarily due to $10.715 million in net proceeds from public offerings and $3.0 million from a promissory note. Total liabilities significantly decreased to $5.539 million from $18.932 million, largely due to a reduction in derivative financial liabilities from $17.421 million to $3 million. The company completed a first-in-human clinical study with a Mean Absolute Relative Difference (MARD) of 7.7% and initiated a long-term clinical study, but faces substantial doubt about its ability to continue as a going concern due to accumulated deficit of $148.210 million and ongoing operating losses.

Why It Matters

Glucotrack's continued operating losses and accumulated deficit of $148.210 million raise significant going concern doubts, directly impacting investor confidence and the company's ability to fund its critical long-term clinical trials. While the 7.7% MARD in its first-in-human study is a promising technical validation for its implantable CBGM, competitive pressures from established CGM players like Dexcom and Abbott mean GCTK needs substantial, sustained financing to bring its product to market. Employees face uncertainty regarding the company's long-term viability, and potential customers await a product that, if successful, could offer a less burdensome diabetes management solution, but its future remains precarious without further capital.

Risk Assessment

Risk Level: high — Glucotrack has an accumulated deficit of $148.210 million as of September 30, 2025, and has generated operating losses and negative cash flow from operations since inception. Management explicitly states these conditions 'raise substantial doubt about the Company's ability to continue as a going concern,' indicating a severe financial risk.

Analyst Insight

Investors should exercise extreme caution and consider GCTK a highly speculative investment. Monitor future financing activities closely, as the company's ability to secure additional capital is paramount to its survival and continued clinical development. Do not invest unless comfortable with significant capital loss risk.

Financial Highlights

total Debt
$5.54M
net Income
-$15.76M
cash Position
$7.87M

Key Numbers

Key Players & Entities

FAQ

What is Glucotrack's current financial liquidity position?

As of September 30, 2025, Glucotrack, Inc. had cash and cash equivalents of $7.869 million. This represents an increase from $5.617 million at December 31, 2024, primarily due to $10.715 million in net proceeds from public offerings and $3.0 million from a promissory note during the nine-month period.

What are the key financial risks for Glucotrack, Inc.?

Glucotrack faces significant financial risks, including an accumulated deficit of $148.210 million as of September 30, 2025, and consistent operating losses and negative cash flow since inception. Management has explicitly stated these conditions raise 'substantial doubt about the Company's ability to continue as a going concern,' indicating a high risk of insolvency without further financing.

How did Glucotrack's operating expenses change in the last quarter?

For the three-month period ended September 30, 2025, Glucotrack's total operating expenses were $4.309 million, an increase from $3.251 million in the same period of 2024. This was primarily driven by research and development expenses rising to $3.165 million from $2.063 million.

What is the status of Glucotrack's clinical trials for its CBGM?

Glucotrack completed a first-in-human short-term clinical study in Q1 2025, which met all primary and secondary endpoints with a Mean Absolute Relative Difference (MARD) of 7.7%. The company has initiated a long-term clinical study outside the United States but is undertaking protocol amendments to refine participant selection criteria and implement product improvements.

What is the Mean Absolute Relative Difference (MARD) for Glucotrack's CBGM?

The first-in-human clinical study for Glucotrack's CBGM demonstrated excellent accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs. This MARD value compares favorably to commercially available continuous glucose monitoring systems.

When does Glucotrack expect to file its IDE submission with the FDA?

Glucotrack initiated discussions with the FDA in Q2 2025 for a pre-investigational device exemption (IDE) submission. The company expects to file the IDE submission to the FDA during the Spring of 2026, subject to accommodating FDA requirements.

How have Glucotrack's shares been affected by reverse stock splits?

Glucotrack implemented a 1-for-20 reverse stock split in February 2025 and a 1-for-60 reverse stock split in June 2025. All shares, options, warrants, and loss per share amounts have been retroactively adjusted to reflect these reverse stock splits for all periods presented.

What is the strategic outlook for Glucotrack's CBGM product?

Glucotrack believes its implantable continuous blood glucose monitor (CBGM), if successful, has the potential to offer a long-term solution with a 3-year sensor longevity, no on-body wearable component, and minimal calibration. The company is focused on advancing its clinical program and securing FDA approval for future U.S. trials.

What was the change in Glucotrack's derivative financial liabilities?

Glucotrack's derivative financial liabilities significantly decreased from $17.421 million as of December 31, 2024, to $3 million as of September 30, 2025. This substantial reduction contributed to the overall decrease in total liabilities.

What is the primary purpose of Glucotrack's CBGM?

The Glucotrack CBGM is being developed as a long-term, fully implantable continuous glucose monitor designed for diabetes patients who depend on daily glucose monitoring. It measures glucose directly from the blood, aiming to eliminate the lag time associated with interstitial fluid glucose monitors and offer a more convenient solution.

Risk Factors

Industry Context

The diabetes management market is characterized by rapid technological advancement, particularly in continuous glucose monitoring (CGM) and implantable devices. Companies are focused on improving accuracy, reducing invasiveness, and extending device longevity. Key trends include integration with insulin delivery systems and data analytics for personalized treatment.

Regulatory Implications

Glucotrack's implantable CBGM will require rigorous regulatory review and approval, likely from the FDA. The company must navigate complex clinical trial requirements and demonstrate safety and efficacy to gain market access, posing a significant hurdle.

What Investors Should Do

  1. Monitor clinical trial progress and outcomes closely.
  2. Assess future financing needs and sources.
  3. Evaluate the competitive landscape and market adoption potential.
  4. Investigate the nature of the reduced derivative financial liabilities.

Key Dates

Glossary

MARD
Mean Absolute Relative Difference. A metric used to evaluate the accuracy of continuous glucose monitoring devices by comparing sensor readings to reference values. (A low MARD (7.7% achieved) indicates high accuracy in the First-In-Human study, a critical performance indicator for the CBGM.)
Accumulated Deficit
The total cumulative net losses of a company since its inception, representing the excess of expenses and losses over revenues and gains. (A large accumulated deficit of $148.210 million is a primary driver for the 'going concern' doubt.)
Derivative Financial Liabilities
Liabilities arising from financial contracts whose value is derived from an underlying asset, index, or rate. These can be complex and volatile. (A significant reduction in these liabilities from $17.421 million to $3 million dramatically improved the company's balance sheet but warrants further investigation into their nature.)
Going Concern
An accounting assumption that a business will continue to operate for the foreseeable future, typically at least 12 months. (The company faces substantial doubt about its ability to continue as a going concern due to its financial condition.)
CBGM
Continuous Blood Glucose Monitor. A device that tracks glucose levels in the body continuously. (Glucotrack is developing an implantable CBGM, with its performance (MARD) and longevity (3-year target) being key product attributes.)

Year-Over-Year Comparison

The nine-month period ending September 30, 2025, shows a widening net loss ($15.76M vs. $12.503M) and increased R&D expenses ($8.19M vs. $7.80M), indicating continued investment in development. However, the company significantly improved its financial position by reducing total liabilities from $18.932M to $5.539M, largely due to a decrease in derivative financial liabilities, and increasing cash reserves to $7.87M from $5.617M. Despite these balance sheet improvements, the going concern risk remains high due to the substantial accumulated deficit.

Filing Stats: 4,581 words · 18 min read · ~15 pages · Grade level 16.2 · Accepted 2025-11-13 16:10:47

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 4

Financial Statements

Item 1. Financial Statements. 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss 5 Condensed Consolidated Statement of Changes in Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 17

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 21

Controls and Procedures

Item 4. Controls and Procedures. 22

- OTHER INFORMATION

PART II - OTHER INFORMATION 23

Legal Proceedings

Item 1. Legal Proceedings 23

Risk Factors

Item 1A Risk Factors 23

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 23

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 23

Other Information

Item 5. Other Information 23

Exhibits

Item 6. Exhibits. 24 EXHIBIT INDEX 24

SIGNATURES

SIGNATURES 25 2 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q (the "Quarterly Report") includes forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects. All statements other than statements of historical fact included in this Quarterly Report, including statements regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words "believe," "expect," "intend," "anticipate," "estimate," "plan," "may," "will," "could," "would," "should" and other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially reali

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing